RxDoctor Payments Data

Martha Tsabetsaye, PA

Physician Assistant · San Diego, CANPI 1700151545

Payments from drug & device makers

$4,133in general payments, 2019–2025

Across 159 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Novo Nordisk$345
  • Amgen$166
  • GSK$152
  • Lilly USA, LLC$115
  • plus $391 from 9 others

What the payments were for

  • Food & beverage$4,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,133 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$54,001
Medicare patients
252
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrezcobixDarunavir/Cobicistat44$109,854
DovatoDolutegravir Sodium/Lamivudine20$63,756
OzempicSemaglutide26$37,147
TivicayDolutegravir Sodium15$33,232
DescovyEmtricitabine/Tenofov Alafenam13$26,711
EliquisApixaban19$25,522
IsentressRaltegravir Potassium11$22,083
Maraviroc11$12,847
Testosterone52$6,116
Carvedilol ErCarvedilol Phosphate13$2,431
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$1,512
Pantoprazole Sodium44$1,321
Methenamine Hippurate19$1,300
Ventolin HfaAlbuterol Sulfate11$947
Pregabalin23$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonPrezcobix$59$109,85444 claims
Viiv Healthcare CompanyDovato, Tivicay$1,734$96,98835 claims
Novo NordiskOzempic$345$37,14726 claims
GileadDescovy$1,230$26,71113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →